MISSISSAUGA, ON, Sept. 25 /CNW/ - Oryx Pharmaceuticals, Inc. (Oryx)
announced today that the IV antibiotic CUBICIN(R) (daptomycin for injection)
is now approved for marketing in Canada. The approval was granted on Monday by
Health Canada. Oryx has licensed CUBICIN for the Canadian market from Cubist
Pharmaceuticals, Inc. (NASDAQ: CBST). The approved label includes both
complicated skin and skin structure infections caused by certain Gram positive
infections, at an approved dose of 4 mg/kg, and bloodstream infections,
including right-sided infective endocarditis, caused by Staphylococcus aureus,
at an approved dose of 6 mg/kg.
